Researchers explored the ability of a peptide targeting the scaffold activity of PI3Kγ to function as a) bronchodilator, b) anti-inflammatory and c) CFTR potentiator. A mouse model of chronic lung inflammation (OVA sensitized mice) and human bronchial epithelial cells (F508del) were used. The peptide significantly elevates cAMP in the airways and limits methacholine-induced airways hyperresponsiveness in OVA mice. In the same model, the peptide reduces the neutrophilic lung inflammation. Finally, in F508del bronchial epithelial cells, it potentiates chloride currents per se and in combination with the gold standard potentiator VX770, upon pharmacological correction with VX809. Optimization of the peptide is ongoing and may pave the way to a peptide based aerosol therapy to be used in combination with standard-of-care CFTR correctors/potentiators.